The Europe Viscosupplementation Market, estimated at USD 310.4 Mn in 2025, is expected to exhibit a CAGR of 5.3% and reach USD 445.6 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Key market players are focused on adopting inorganic growth strategies such as partnership which will drive the Europe viscosupplementation market. For instance, on March 03, 2025, Lifecore Biomedical, Inc., a contract manufacturing organization (CDMO), has entered into a term sheet to expand its existing CDMO relationship with one of its long-term commercial Hyaluronic Acid and CDMO customers, including obtaining certain up-front cash payments and capital reimbursement obligations from the customer and entering an agreement to amend the current contract manufacturing agreement (CMA) with the customer to extend and expand the relationship.
Europe Viscosupplementation Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated te illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of equipment from one place to another.
For instance, For instance, ion Janaury 2025, Fidia Farmaceutici S.p.A., a key player in the manufacturing of hyaluronic acid-derived products, introduced the TRILURON product. The product is a viscosupplement which is manufactured for the treatment of osteoarthritis pain of the knee. To gain the loyalty and trust of customers, key manufacturers are preparing for the post-impact of COVID-emergency. These strategic product innovations may offer lucrative market opportunities for viscosupplementation treatment after the COVID-19 pandemic.
Europe Viscosupplementation Market: Key Developments
In January, 2025, OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions including osteoarthritis (OA), has announced the launch of TriVisc (sodium hyaluronate) for the treatment of patients with osteoarthritic (OA) knee pain who have failed to get adequate relief from simple painkillers or from exercise and physical therapy. TriVisc is a solution of highly purified hyaluronic acid (sodium hyaluronate; HA) and helps supplement the viscous properties of the fluid in the knee joint. TriVisc is administered by a healthcare professional in 3 injections in the knee given at weekly intervals. In clinical studies TriVisc has been shown to provide patients with months of pain relief and can be repeated if the pain returns.